[Primary prevention of cardiovascular disease with statin in type 2 diabetes mellitus: Is it time to change our strategy?]

Med Clin (Barc). 2014 Apr 22;142(8):358-9. doi: 10.1016/j.medcli.2014.01.003. Epub 2014 Mar 3.

[Article in Spanish]

Authors

Lara Albert Fàbregas¹, José Miguel González-Clemente²

Affiliations

¹ Servicio de Endocrinología y Nutrición, Hospital de Sabadell, Corporació Sanitària i Universitària Parc Taulí, Universidad Autónoma de Barcelona, Sabadell, Barcelona, España.
² Servicio de Endocrinología y Nutrición, Hospital de Sabadell, Corporació Sanitària i Universitària Parc Taulí, Universidad Autónoma de Barcelona, Sabadell, Barcelona, España. Electronic address: josmi.gonza@gmail.com.

PMID: 24602748
DOI: 10.1016/j.medcli.2014.01.003

No abstract available

Publication types

Editorial

MeSH terms

Adult
Aged
Cardiovascular Diseases / epidemiology
Cardiovascular Diseases / etiology
Cardiovascular Diseases / prevention & control*
Clinical Trials as Topic
Cost-Benefit Analysis
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Disease Management*
Drug Substitution / economics
Drugs, Generic / economics
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors / economics
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hypercholesterolemia / prevention & control
Middle Aged
Multicenter Studies as Topic
Primary Prevention
Risk Assessment
Risk Factors
Severity of Illness Index
Spain / epidemiology

Substances

Drugs, Generic
Hydroxymethylglutaryl-CoA Reductase Inhibitors